TELA TELA Bio

TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference

TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference

MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12th, 2023.

TELA’s management is scheduled to present at 11:15 am ET on January 12th, 2023. Interested parties can access the live and archived webcast at .

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit .

Investor Contact

Greg Chodaczek

332-895-3230



EN
21/12/2022

Underlying

TELATELA Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Reports Second Quarter 2025 Financial Results

TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...

10h / 54m 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted ...

August 8, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...

July 23, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Announce Second Quarter 2025 Financial Results

TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...

July 21, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...

June 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch